AACR 2012: ABT-199 shows promise in CLL
At the 2012 annual meeting of the American Association for Cancer Research (AACR), Steven W. Elmore from Abbott Laboratories presented impressive initial data on ABT-199, a potent and selective inhibitor of Bcl-2, currently in a phase I clinical trial for Chronic Lymphocytic Leukemia (CLL).
- — Naoto T. Ueno 上野直人 (@teamoncology)Sun, Apr 01 2012 13:34:42
- — Ronak Savla (@OracleofPharma)Sun, Apr 01 2012 13:43:37RT @3NT: Elmore: a single-dose of ABT-199 can achieve rapid reduction of CLL burden in patients with refractory disease - data at EHA 2012 #aacr
- — Mike Thompson, MDPhD (@mtmdphd)Thu, Apr 05 2012 13:57:42
Did you find this story interesting? Be the first to like or comment.